Research suggests that short-term dual antiplatelet therapy (DAPT) may be sufficient for patients undergoing percutaneous coronary intervention (PCI) with ultrathin drug-eluting stents. Some studies, including the HOST-IDEA trial, indicate that short DAPT is noninferior to longer durations, while others explore the efficacy of short DAPT with specific stent types or patient populations. The optimal duration of DAPT remains a topic of investigation, with varying results reported across different studies and patient groups.